التفاصيل البيبلوغرافية
| العنوان: |
P13 kinase gamma inhibitors for the treatment of anaemia |
| Document Number: |
20090042773 |
| تاريخ النشر: |
February 12, 2009 |
| Appl. No: |
11/664969 |
| Application Filed: |
October 11, 2005 |
| مستخلص: |
This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia. (I) wherein A, X, Y1, Y2, Z, n, R1 and R2 are described in details in the description hereinafter. [chemical expression included] |
| Inventors: |
Wetzker, Reinhard (Jena, DE); Mueller, Angelika (Jena, DE); Rommel, Christian (Geneva, CH) |
| Claim: |
1-18. (canceled) |
| Claim: |
19. A method of treating a subject with a disorder related to erythrocyte deficiency, comprising administering to the subject an effective amount of a selective PI3 Kinase gamma inhibitor. |
| Claim: |
20. The method according to claim 19, further comprising administering to the subject an effective amount of erythropoetin (EPO), a variant, or an analogue thereof. |
| Claim: |
21. The method according claim 19, wherein the disease is anaemia. |
| Claim: |
22. The method according to claim 21, wherein the disease is haemolytic anaemia, aplastic anaemia, or pure red cell anaemia. |
| Claim: |
23. The method according to claim 19, wherein the PI3 Kinase gamma inhibitor is a compound according to formula (I) [chemical expression included] as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl; X is S, O or NH; Y1 and Y2 are independently S, O or —NH; Z is S or O; R1 is H, CN, carboxy, acyl, C1-C6 alkoxy, halogen, hydroxy, acyloxy, C1-C6-alkyl carboxy, C1-C6-alkyl acyloxy, C1-C6-alkyl alkoxy, alkoxycarbonyl, C1-C6-alkyl alkoxycarbonyl, aminocarbonyl, C1-C6-alkyl aminocarbonyl, acylamino, C1-C6-alkyl acylamino, ureido, C1-C6-alkyl ureido, amino, C1-C6-alkyl amino, ammonium, sulfonyloxy, C1-C6-alkyl sulfonyloxy, sulfonyl, C1-C6-alkyl sulfonyl, sulfinyl, C1-C6-alkyl sulfinyl, sulfanyl, C1-C6-alkyl sulfanyl, sulfonylamino, C1-C6-alkyl sulfonylamino or carbamate; R2 is selected from the group comprising or consisting of H, halogen, acyl, amino, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkyl carboxy, C1-C6-alkyl acyl, C1-C6-alkyl alkoxycarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acyloxy, C1-C6-alkyl acylamino, C1-C6-alkyl ureido, C1-C6-alkyl amino, C1-C6-alkyl alkoxy, C1-C6-alkyl sulfanyl, C1-C6-alkyl sulfinyl, C1-C6-alkyl sulfonyl, C1-C6-alkyl sulfonylaminoaryl, aryl, C3-C8-cycloalkyl or heterocycloalkyl, C1-C6-alkyl aryl, C2-C6-alkenyl-aryl, C2-C6-alkynyl aryl, carboxy, cyano, hydroxy, C1-C6-alkoxy, nitro, acylamino, ureido, C1-C6-alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl; n is 0, 1 or 2. |
| Claim: |
24. The method according to claim 23, wherein Y1 and Y2 are both oxygen. |
| Claim: |
25. The method according to claim 23, wherein n is 1 or 2 and R1 and R2 are both H. |
| Claim: |
26. The method according to claim 23, wherein X is S, Y1 and Y2 are O, R1 and R2 are both H and n is 0. |
| Claim: |
27. The method according to claim 23, wherein the PI3 Kinase gamma inhibitor is a compound according to formula (II-a) [chemical expression included] or a pharmaceutically acceptable salt thereof, wherein: A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxazinyl, pyridinyl, isooxazolyl, oxazolyl (dihydro)napthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, oxadiazolyl; R2 is selected from the group comprising or consisting of H, halogen, acyl, amino, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkyl carboxy, C1-C6-alkyl acyl, C1-C6-alkyl alkoxycarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acyloxy, C1-C6-alkyl acylamino, C1-C6-alkyl ureido, C1-C6-alkyl carbamate, C1-C6-alkyl amino, C1-C6-alkyl alkoxy, C1-C6-alkyl sulfanyl, C1-C6-alkyl sulfinyl, C1-C6-alkyl sulfonyl, C1-C6-alkyl sulfonylaminoaryl, aryl, C3-C8-cycloalkyl or heterocycloalkyl, C1-C6-alkyl aryl, C2-C6-alkenyl-aryl, C2-C6-alkynyl aryl, carboxy, cyano, hydroxy, C1-C6-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, or sulfonyl. |
| Claim: |
28. The method according to claim 23, wherein the PI3 Kinase gamma inhibitor is a compound according to formula (II) [chemical expression included] as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein n is 0 or 1. |
| Claim: |
29. The method according to claim 28, wherein Y1 is O. |
| Claim: |
30. The method according to claim 28, wherein R1 is selected from the group consisting of C1-C6-alkyl, C1-C6-alkyl aryl, aryl, C3-C8-cycloalkyl or heterocycloalkyl, C1-C6-alkyl aryl, C2-C6-alkenyl-aryl and C2-C6-alkynyl aryl. |
| Claim: |
31. The method according to claim 23, wherein the PI3 Kinase gamma inhibitor is a compound according to formula (III) [chemical expression included] as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof. |
| Claim: |
32. The method according to claim 23, wherein the PI3 Kinase gamma inhibitor is a compound according any of the formulae (IV), (V) and (VI) [chemical expression included] or a pharmaceutically acceptable salt thereof; wherein R1 is selected from the group consisting of hydrogen, halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, acyl, alkoxy carbonyl. |
| Claim: |
33. The method according to claim 19, wherein the PI3 Kinase gamma inhibitor is a compound to formula (I′), [chemical expression included] or a pharmaceutically acceptable salt thereof; wherein A is an 5-8 membered heterocyclic group or an carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl; X is S, O or —NR3; Y is S or O; R1 is selected from the group comprising or consisting of H, CN, carboxy, acyl, C1-C6-alkoxy, halogen, hydroxy, acyloxy, C1-C6-alkyl carboxy, C1-C6-alkyl acyloxy, C1-C6-alkyl alkoxy, alkoxycarbonyl, C1-C6-alkyl alkoxycarbonyl, aminocarbonyl, C1-C6-alkyl aminocarbonyl, acylamino, C1-C6-alkyl acylamino, ureido, C1-C6-alkyl ureido, amino, C1-C6-alkyl amino, ammonium, sulfonyloxy, C1-C6-alkyl sulfonyloxy, sulfonyl, C1-C6-alkyl sulfonyl, sulfinyl, C1-C6-alkyl sulfinyl, sulfanyl, C1-C6-alkyl sulfanyl, sulfonylamino, C1-C6-alkyl sulfonylamino or carbamate; R2 is selected from the group comprising or consisting of H, halogen, acyl, amino, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkyl carboxy, C1-C6-alkyl acyl, C1-C6-alkyl alkoxycarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acyloxy, C1-C6-alkyl acylamino, C1-C6-alkyl ureido, C1-C6-alkyl carbamate, C1-C6-alkyl amino, C1-C6-alkyl alkoxy, C1-C6-alkyl sulfanyl, C1-C6-alkyl sulfinyl, C1-C6-alkyl sulfonyl, C1-C6-alkyl sulfonylaminoaryl, aryl, heteroaryl, C3-C8-cycloalkyl or heterocycloalkyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C2-C6-alkenyl-aryl or -heteroaryl, C2-C6-alkynyl aryl or -heteroaryl, carboxy, cyano, hydroxy, C1-C6-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, or sulfonyl; G is a C1-C6-alkyl, C2-C6-alkyenyl, C2-C6-alkynyl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C2-C6-alkenyl-aryl or -heteroaryl, C2-C6-alkynyl aryl or -heteroaryl, C1-C6-alkoxy, cyano, C1-C6-acyl, or a sulfonyl moiety. R3 is selected from the group comprising or consisting of H or C1-C6-alkyl. |
| Claim: |
34. The method according to claim 19, wherein the PI3 Kinase gamma inhibitor is a compound selected from the group consisting of: 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione; 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-thiazolidin-4-one; 5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-1,3-thiazolidine-2,4-dione; 5-(2,3-dihydro-1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione; 5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-[(9,10-dioxo-9,10-dihydroanthracen-2-yl)methylene]-1,3-thiazolidine-2,4-dione; (5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione; (5Z)-5-(1,3-dihydro-2-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione; 5-(1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione; 5-[(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-(1,3-benzodioxol-5-ylmethylene)-2-imino-1,3-thiazolidin-4-one; 5-Quinolin-6-ylmethylene-thiazolidine-2,4-dione; 5-Quinolin-6-ylmethylene-2-thioxo-thiazolidin-4-one; 2-Imino-5-quinolin-6-ylmethylene-thiazolidin-4-one; 5-(3-Methyl-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione; 5-(4-Phenyl-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione; 5-(4-Dimethylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione; 5-[(4-aminoquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-[(4-piperidin-1-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-[(4-morpholin-4-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-{[4-(benzylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-{[4-(diethylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-({4-[(pyridin-2-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({4-[(pyridin-3-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione; ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-3-carboxylate; ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate; tert-butyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}-L-prolinate; 5-{[4-(4-methylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-{[4-(4-pyrimidin-2-ylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-({4-[4-(4-fluorophenyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-{[4-(4-benzylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-({4-[4-(2-phenylethyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-{[4-(4-methylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-{[4-(4-hydroxypiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-4-carboxylic acid; 1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-3-carboxylic acid; 1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-pyrrolidine-2-carboxylic acid; 5-(4-Methylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione; 5-(4-Methoxy-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione; 2-Imino-5-(4-methylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one; 2-Imino-5-((4-(piperidin-1-yl)quinazolin-6-yl)methylene)-thiazolidin-4-one; 2-Imino-5-(4-dimethylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one; 5-(2-Methyl-2H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione; 5-(3-Methyl-3H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione; 5-(3-Ethyl-3H-benzoimidazol-5-ylmethylene)-thiazolidine-2,4-dione; 5-{[1-(4-phenylbutyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-[(1-prop-2-yn-1-yl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-[(1-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-({1-[2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; methyl 4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-yl}cyclohexanecarboxylate; 5-({1-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({1-[2-(4-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({1-[4-(trifluoromethyl)benzyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-yl}cyclohexanecarboxylic acid; 5-[(1-isobutyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-({1-[2-(1,3-benzodioxol-4-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({1-[2-(2-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-{[1-(3,3-diphenylpropyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-{[1-(2-methoxybenzyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-{[1-(3-furylmethyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-[(1-propyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione; 5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione; 5-Quinoxalin-6-ylmethylene-2-thioxo-thiazolidin-4-one; 2-Imino-5-quinoxalin-6-ylmethylene-thiazolidin-4-one; 5-Benzothiazol-6-ylmethylene-thiazolidine-2,4-dione; 5-(3-Methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione; 5-(2-Bromo-3-methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione; 5-(3-bromo-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione; 3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid ethyl ester; 3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid; 5-[3-(3-Oxo-3-piperidin-1-yl-propenyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione; Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)prolinate; Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-D-prolinate; 5-({3-[3-oxo-3-pyrrolidin-1-ylprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({3-[3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-L-prolinate; N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-methylacrylamide; 3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-ethyl-N-(2-hydroxyethyl)acrylamide; N-cyclobutyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide; 5-({3-[3-azetidin-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({3-[3-(1,3-dihydro-2H-isoindol-2-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; 5-({3-[3-azepan-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; 3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-piperidin-1-ylacrylamide; 3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-(pyridin-3-ylmethyl)acrylamide; N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide; 5-({3-[3-(4-methylpiperazin-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; N-cycloheptyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide; 5-({3-[3-(2,5-dihydro-1H-pyrrol-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione; N-cyclopentyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide; 3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid ethyl ester; 3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid; 5-[3-(3-Oxo-3-piperidin-1-yl-propyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione; 6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester; 5-(3,4-Dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione; 5-(4-Benzoyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione; 5-(4-Acetyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione; 6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester; [6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-acetic acid methyl ester; N-Benzyl-2-[6-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl]-acetamide; 5-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione; 5-(4-Benzyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione; 5-(2-Chloro-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione; 5-(3-Amino-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione; 5-(3-Phenylethynyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione; 5-Benzo[1,2,5]thiadiazol-5-ylmethylene-thiazolidine-2,4-dione; 5-Benzo[1,2,5]oxadiazol-5-ylmethylene-thiazolidine-2,4-dione; 5-(2-Methyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione; 5-(2-Carboxymethyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione; 5-(3-Bromo-2-fluoro-2,3-dihydro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione; 5-(2-Fluoro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione; N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-2-chlorobenzenesulfonamide; Ethanesulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide; N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-3-chlorobenzenesulfonamide; 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)amide; 3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester; 6-Chloro-pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)amide; Quinoline-8-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)amide; N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-benzenesulfonamide; N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-4-methylbenzenesulfonamide; N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-methanesulfonamide; N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-benzenesulfonamide; N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-4-methyl-benzenesulfonamide; N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-methanesulfonamide; Biphenyl-2-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)amide; Pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)amide; 3-(4-Oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester; 2-Chloro-N-(4-oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidene)-benzenesulfonamide; 3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid; 5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene-cyanamide; 5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione 2-(O-methyl-oxime); 4-Oxo-5-quinoxalin-6-ylmethylene-thiazolidin-2-ylidene-cyanamide; 5-Benzo[1,3]dioxol-5-ylmethylene-2-benzylimino-thiazolidin-4-one; 2-Benzylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one; 2-Propylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one; 5-Benzo[1,3]dioxol-5-ylmethylene-2-propylimino-thiazolidin-4-one; and 5-(4-Dimethylamino-quinazolin-6-ylmethylene)-2-methylamino-thiazol-4-one; or a pharmaceutically acceptable salt thereof. |
| Claim: |
35. A composition comprising an erythropoetin (EPO), a variant, or an analogue thereof, a PI3 Kinase gamma inhibitor according to claim 19 and a pharmaceutically acceptable excipient. |
| Claim: |
36. A composition according to claim 35 which is an injectable liquid. |
| Current U.S. Class: |
514/8 |
| Current International Class: |
61; 61; 61; 61; 61; 61 |
| رقم الانضمام: |
edspap.20090042773 |
| قاعدة البيانات: |
USPTO Patent Applications |